Verum.de
, a full-clinical service, German-based contract research organization (CRO) with a new office in Carlsbad, Calif., has entered into an agreement with the
Center for Oncologic Diagnosis and Treatment
(Oncocard) in Romania to be its preferred provider of clinical trial services. The center, developed with the first private investment funding in oncology in Romania, is brand new and features state-of-the-art services and equipment. The center selected Verum.de as their CRO of choice so they could assist with
running clinical trials
and offer patients all possible treatment options.
“The esteemed medical professionals involved with the center provide patients a sophisticated level of treatment and services that are rare for the area,” stated Verum’s local Romanian Medical Director Laurentiu Nedelcu, a doctor and pharmacologist who has supervised Verum trials since 1996. “Verum is known for its
regional expertise
, and we’re pleased to be the CRO the center has chosen to work with.”
The
Oncology Center
, which opened in June, 2012, is a 86,112 sq. feet clinic offering full spectrum oncologic chemotherapy, radiotherapy, treatment of hematological malignancies
and surgical services to patients in addition to serving as an investigative center for research. The Oncology Center’s medical staff is highly qualified and many of the Oncology Center’s staff doctors have experience working with Verum. To date, more than 1,700 patients have been treated at the facility and more than 3,800 investigations have been performed.
“The center was opened to offer a higher level of care to cancer patients, with the best services and equipment modern medicine has available,” explained the center’s Medical Director, Dr. Mihai Ciochinaru. “We trust working with a CRO such as Verum, which runs trials in an efficient, highly ethical manner and understands the region.”
Verum provides
clinical trial services
with Western standards in Central and Eastern European countries (CEE) and former Soviet bloc countries. Verum recently opened a U.S. office in Carlsbad to assist U.S. clients with international trials, and the
new office
is headed by Kristi Clark, an industry veteran with more than 20 years of pharma and biotech experience in both large and mid-size CROs.
Related Links:How CROs Help Oncology Sponsors Produce Results
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.